Skip to Content

Yiling Lu, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

My research focuses on identifying and characterizing novel cellular targets for cancer therapy by Systems Biology approach. Cancer systems biology demonstrates that multiple genomic aberrations in cancer cells integrate at the protein level to alter cellular functions. For the past years, I have spent my major efforts to develop and validate the technology of Reverse Phase Protein Arrays (RPPA) in its application of cancer systems biology. RPPA provides robust information to integrate the consequence of genetic aberrations in cancer, to validate therapeutic targets, to demonstrate on- and off-target activity of drugs and to evaluate drug pharmacodynamics. It also characterizes, across large numbers of samples or cell lines, the basal protein expression levels, growth factor- or ligand-induced effects and time resolved responses appropriate for systems biology analysis. To better understand cancer pathobiology, we have joined TCGA program and characterized signaling networks in 3649 cancer samples across different diseases. In addition, we have completed screenings by RPPA with (a) 779 siRNAs targeting protein and lipid kinases; (b) 879 human genome miRNAs; and (c) multiple drug libraries in breast and ovarian cancer cells aiming to identify novel cellular targets for cancer therapy. The studies builds up a “fingerprint” of activity from chemical and genetic manipulations that can rapidly identify novel therapeutic targets as well as determine actions of unknown molecules. As a CCSG RPPA Core director, I have demonstrated myself as a leadership in the field to provide M. D. Anderson investigators and the larger research community around the world with our expertise on functional proteomics studies. Further, I have extensive experiences in collaboration with investigators nationwide and we have successfully completed multiple projects, especially on the studies targeting PI3K-AKT pathway in breast and ovarian cancers. In summary, I have prepared myself as a successful and productive cancer researcher with major contribution to the field of targeted cancer therapy by proteomics approach. My expertise and experiences will lead to the completion of the proposed project. 

Office Address

The University of Texas MD Anderson Cancer Center
7435 Fannin Street
Unit Number: 0950
Houston, TX 77054
Room Number: 2SCR3.3022

Education & Training

Degree-Granting Education

1987 Shanghai Second Medical University, Shanghai, China, MS, Immunology and Microbiology
1977 Shanghai Second Medical University, Shanghai, China, MD, Medicine (equivalent to U.S. M.D. by educational evaluation at Span Tran Services)

Postgraduate Training

7/1989-4/1996 Research Fellowship, Internal Medicine, Texas Tech University-Health Sciences Center, Amarillo, TX, James Trevillyan
9/1988-6/1989 Research Fellowship, Pathology, University of Iowa Hospitals and Clinics, Iowa City, TX, John D. Kemp


Academic Appointments

Assistant Professor, Systems Biology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1/1999-8/2008
Research Associate, Systems Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 4/1996-12/1998
Postdoctoral Research Associate, Department of Internal Medicine, Texas Tech University, Amarillo, TX, 7/1989-4/1996
Research Fellow, Department of Pathology - Research, Division of Pathology/Lab Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 9/1988-6/1989
Instructor, Department of Immunology, Shanghai Second Medical University, Shanghai, China, China, 1/1986-1/1988
Research Assistant, Department of Immunology, Shanghai Second Medical University, Shanghai, China, 1/1977-1/1985

Selected Publications

Peer-Reviewed Original Research Articles

1. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS 3), an imprinted tumor suppressor gene, binds to importins, and blocks nuclear import process of cargo proteins. Biosci Rep 30(3):159-68, 6/2010. e-Pub 5/2009. PMID: 19435463.
2. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, Artavanis-Tsakonas S, Brugge JS. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 107(11):5012-7, 3/16/2010. e-Pub 3/1/2010. PMCID: PMC2841923.
3. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2/2010. e-Pub 2/2/2010. PMID: 20124458.
4. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-54, 2/2010. e-Pub 9/2009. PMID: 19730444.
5. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21-32, 7/2009. PMCID: PMC2752826.
6. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 4/2009. PMCID: PMC2673492.
7. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 12/2008. e-Pub 11/20/2008. PMCID: PMC2582930.
8. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100(22):1630-42, 11/2008. e-Pub 11/2008. PMCID: PMC2720766.
9. Ji Y, Lu Y, Mills GB. Bayesian methods based on test statistics for multiple hypothesis testing problems. Bioinformatics 24(7):943-949, 2008. PMID: 18245123.
10. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, and Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nature Genetics 39(4):503-512, 2007.
11. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. ACTN4 Regulates AKT1 Function: A Retrovirus-Based Protein Mammalian Complementation Assay Screen Reveals Novel AKT1 Binding Partners. Proc Natl Acad Sci U S A 103(41):15014-19, 10/2006. e-Pub 10/2006. PMCID: PMC1636760.
12. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3)(3):225-238, 3/2006. PMID: 16530706.
13. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4(4):346-55, 4/2005. e-Pub 1/25/2005. PMID: 15671044.
14. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057-66, 10/10/2003. e-Pub 7/17/2003. PMID: 12869565.
15. Lu Y, Shayesteh L, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102, 1999. PMID: 9916799.
16. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18:7034-45, 1999. PMID: 10597304.

Last updated: 2/28/2013